Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues

Schizophrenia Bulletin

Volumn 23, Issue 2, 1997, Pages 247-254

  Ziedonis, Douglas M ^a   George, Tony P ^b  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; DRUG DEPENDENCE; FEMALE; HEALTH PROMOTION; HUMAN; MALE; MOTIVATION; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SMOKING CESSATION; WITHDRAWAL SYNDROME;

EID: 0031007393     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/23.2.247     Document Type: Article

References (61)

1. Adler, L.E.; Hoffer, L.; Wiser, A.; and Freedman, R. Normalization of auditory physiology by cigarette smoking schizophrenic patients. American Journal of Psychiatry, 150:1856-1861, 1993.
2. Albanese, M.J.; Khantzian, E.J.; Murphy, S.L.; and Green, A.I. Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151:780-781, 1994.
3. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
4. Andreasen, N.C. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa, 1984a.
5. Andreasen, N.C. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1984b.
6. Balfour, D.J. Neural mechanisms underlying nicotine dependence. Addiction, 89:1419-1423, 1994.
7. Baron, J.A. Cigarette smoking and Parkinson's Disease. Neurology, 36:1490-1496, 1986.
8. Benowitz, N.L., and Henningfield, J.E. Establishing a nicotine threshold for addiction: The implications for tobacco regulation. New England Journal of Medicine, 331:123-126, 1994.
9. Binder, R.L.; Kazamatsuri, H.; Nishimura, T.; and McNiel, D.E. Smoking and tardive dyskinesia. Biological Psychiatry, 22:1280-1282, 1987.
10. Breslau, N. Psychiatric comorbidity of smoking and nicotine dependence. Behavioral Genetics, 25(2):95-101, 1995.
11. Brioni, J.D.; Kim, D.J.B.; O'Neill, A.B.; Williams, J.E.G.; and Decker, M.W. Clozapine attenuates the discriminative stimulus properties of (-)nicotine. Brain Research, 643:1-9, 1994.
12. Buckley, P.; Thompson, P.; Way, L.; and Meltzer, H.Y. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151:385-389, 1994.
13. Carr, L.A.; Rowell, P.P.; and Pierce, W.M. Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochemical Research, 14:511-515, 1989.
14. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993.
15. Clarke, P.B., and Pert, A. Autoradiographic evidence of nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Research, 348:355-358, 1985.
16. Corrigall, W.A.; Franklin, K.B.J.; Coen, K.M.; and Clarke, P.B.S. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology, 107:285-289, 1992.
17. Dalack, G.W.; Becks, L.; Hill, E.; Pomerleau, O.; and Meador-Woodruff, J.H. "Nicotine Withdrawal and Psychiatric Symptoms in Cigarette Smokers With Schizophrenia." Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 1996.
18. Dalack, G.W., and Glassman, A.H. A clinical approach to help psychiatric patients with smoking cessation. Psychiatric Quarterly, 63:27-39, 1992.
19. Dani, J.A., and Heinemann, S. Molecular and cellular aspects of nicotine abuse. Neuron, 16:905-908, 1996.
20. Decina, P.; Caracci, G.; Sandik, R.; Berman, W.; Mukerjee, S.; and Scapicchio, P. Cigarette smoking and neuroleptic-induced parkinsonism. Biological Psychiatry, 28:502-508, 1990.
21. Docherty, J.P.; Marzuk, P.M.; and Barchas, J.D. Nicotine dependence: Perspectives on a new guideline from the American Psychiatric Association. American Journal of Psychiatry, 153(10): 1247-1248, 1996.
22. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Pappas, N.; Logan, J.; MacGregor, R.; Alexoff, D.; Shea, C.; Schlyer, D.; Wolf, A.P.; Warner, D.; Zewzulkova, I.; and Cilento, R. Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379:733-736, 1996.
23. 4 dopamine receptor alleles in chronic alcoholism. Biochemistry and Biophysics Research Communication, 196:107-114, 1993.
24. George, T.P.; Sernyak, M.J.; Ziedonis, D.M.; and Woods, S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry, 56:344-346, 1995.
25. Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. American Journal of Psychiatry, 150:546-553, 1993.
26. Goff, D.C.; Henderson, D.C.; and Amico, E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. American Journal of Psychiatry, 149:1189-1194, 1992.
27. Hall, R.G.; Duhamel, M.; McClanahan, M.G.; Nason, D.; Rosen, S.; Schiller, P.; Tao-Yonenaga, L.; and Hall, S. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. Journal of Nervous and Mental Disease, 183:468-471, 1995.
28. Hameedi, F.A.; Farren, C.K.; Rosen, M.I.; Pearsall, H.R.; Woods, S.W.; and Kosten, T.R. "Serotonin Dopamine Antagonists in Treatment of Cocaine Abuse" [Abstract NR477]. Presented at the Annual Meeting of the American Psychiatric Association, Miami, FL, May 1995. p. 183.
29. Hasegawa, M.; Gutierrez-Esteinou, R.; Way, L.; and Meltzer, H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effects of smoking. Journal of Clinical Psychopharmacology, 13:383-390, 1993.
30. Heath, A.C., and Martin, N.G. Genetic models for the natural history of smoking: Evidence for a genetic influence on smoking persistence. Addictive Behaviors, 18:19-34, 1993.
31. Hughes, J.R. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Journal of Clinical Psychiatry, 54:109-114, 1993.
32. Hughes, J.R.; Hatsukami, D.K.; Mitchell, J.E.; and Dahlgren, L.A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143:993-997, 1986.
33. Imperato, A.; Mulas, A.; and DiChiara, G. Nicotine preferentially stimulates dopamine release in the limbic system in freely moving rats. European Journal of Pharmacology, 90:468-470, 1986.
34. Kane, J.M.; Honigfeld, G.; Singer, J.; and Meltzer, H.Y. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
35. Karler, R.; Calder, L.D.; Thai, L.H.; and Bedingfield, J.B. The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine. Brain Research, 671:100-104, 1995.
36. Kessler, D.A. Nicotine addiction in young people. New England Journal of Medicine, 333:186-189, 1995.
37. Kosten, T.A., and Nestler, E.J. Clozapine attenuates cocaine conditioned place preference. Life Sciences, 55:PL9-PL14, 1994.
38. Lohr, J.B., and Flynn, K. Smoking and schizophrenia. Schizophrenia Research, 8:93-102, 1992.
39. MacKenzie, T.D.; Bartecchi, C.E.; and Schrier, R.W. The human costs of tobacco. Part 2. New England Journal of Medicine, 330:975-980, 1994.
40. McEvoy, J.P.; Freudenreich, O.; McGee, M.; VanderZwaag, C.; Levin, E.; and Rose, J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry, 37:550-552, 1995.
41. McGehee, D.S.; Heath, M.J.S.; Gelber, S.; Devay, P.; and Role, L.W. Nicotine enhancement of fast excitatory synaptic transmission in the CNS by presynaptic receptors. Science, 269:1692-1696, 1995.
42. Menza, M.A.; Grossman, N.; Van Horn, M.; Cody, R.; and Forman, N. Smoking and movement disorders in psychiatric patients. Biological Psychiatry, 30:109-115, 1991.
43. Merea, G.; Yoon, K.W.; Boi, V.; Lessa, G.L.; Naes, L.; and Westfall, T.C. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. European Journal of Pharmacology, 141:395-399, 1987.
44. Miller, W.R., and Rollnick, S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guilford Press, 1991.
45. Miller, W.R.; Zweben, A.; DiClemente, C.C.; and Rychtarik, R.G. Motivational Enhancement Therapy Manual. Rockville, MD: U.S. Department of Health and Human Services, Publication No. (ADM) 92-1894, 1992.
46. Moghaddam, B., and Bunney, B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. Journal of Neurochemistry, 54:1755-1760, 1990.
47. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Washington, DC: Alcohol, Drug Abuse, and Mental Health Administration, U.S. Department of Health, Education, and Welfare, 1974.
48. Nemeroff, C.G.; DeVane, C.L.; and Pollock, B.G. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153:311-320, 1996.
49. Nisell, M.; Nomikos, G.; and Svensson, T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacology and Toxicology, 76:157-162, 1995.
50. 2 dopamine receptor gene and cigarette smoking: A reward gene? Medical Hypothesis, 42:257-260, 1994.
51. Paulson, G.W. Addiction to nicotine is due to high intrinsic levels of dopamine. Medical Hypothesis, 38:206-207, 1992.
52. Perry, P.J.; Miller, D.D.; Arndt, S.V.; Smith, D.A.; and Holman, T.L. Haloperidol dosing requirements: The contributions of smoking and nonlinear pharmacokinetics. Journal of Clinical Psychopharmacology, 13:46-51, 1993.
53. Pomerleau, O.F. Nicotine and the central nervous system: Biobehavioral effects of cigarette smoking. American Journal of Medicine, 93:1A-7S, 1992.
54. Prochaska, J.O., and DiClemente, C.C. Stages and processes of self-change of smoking: Toward an integrative model of change. Journal of Consulting and Clinical Psychology, 51(3):390-395, 1983.
55. Satel, S.L.; Krystal, J.H.; Delgado, P.L.; Kosten, T.R.; and Charney, D.S. Tryptophan depletion and attenuation of cue-induced craving for cocaine. American Journal of Psychiatry, 152:778-783, 1995.
56. Spencer, D.D.; Robbins, R.J.; Naftolin, F.; Marek, K.L.; Vollmer, T.; Leranth, C.; Roth, R.H.; Price, L.H.; Gjedde, A.; Bunney, B.S.; Sass, K.J.; Elsworth, J.D.; Kier, E.L.; Makuch, R.; Hoffer, P.B.; and Redmond, D.E., Jr. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. New England Journal of Medicine, 327:1541-1548, 1992.
57. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350:610-614, 1991.
58. Vidal, C. Nicotine potentiation of glutamatergic synapses in the prefrontal cortex: New insight into the analysis of the role of nicotinic receptors in cognitive functions. Drug Development Research, 31:120-126, 1994.
59. Yassa, R.; Lal, S.; Korpassy, A.; and Ally, J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry, 22:67-72, 1987.
60. Ziedonis, D.M., and Fisher, W. Motivation-based assessment and treatment of substance abuse in patients with schizophrenia. Directions in Psychiatry, 16(11):1-8, 1996.
61. Ziedonis, D.M.; Kosten, T.R.; Glazer, W.M.; and Frances, R.J. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry, 45:204-206, 1994.